Hi NZT and all,
Good to see you onboard NZT you have a well deserved following via HC.
The potential for Psilocybin use in the USA is gaining traction.
Two bills have already been introduced into the USA House of Representatives and are awaiting approval.
Think of this Company if and when it possibly gets approved. The rationale below.
Both the Breakthrough Therapies Act (S.689) and the Douglas 'Mike' Day Psychedelic Therapy to Save Lives Act (H.R.3684) have bipartisan support, which increases their chances of passage. However, their success depends on various factors, including political dynamics, public opinion, and prioritization within Congress. Here's an analysis of their likelihood of passage:
Breakthrough Therapies Act (S.689)
Bipartisan Support: Senators Cory Booker and Rand Paul have reintroduced this bill with backing from both parties, indicating strong legislative momentum.
Purpose: The Act aims to reschedule Schedule I substances (e.g., MDMA and psilocybin) to Schedule II for research and compassionate use, reducing regulatory hurdles.
Challenges: Despite bipartisan support, there may still be resistance from lawmakers concerned about substance misuse or broader implications of rescheduling controlled substances.
Likelihood: Given growing public and scientific support for psychedelic therapies, the bill has a reasonable chance of passage by 2026, especially if advocates continue to emphasize its potential for life-saving treatments.
Douglas 'Mike' Day Psychedelic Therapy to Save Lives Act (H.R.3684)
Progress: A provision of this bill was already signed into law as part of the National Defense Authorization Act (NDAA), directing the Department of Defense to fund research into psychedelics for PTSD and traumatic brain injury.
Bipartisan Coalition: The bill has widespread bipartisan sponsorship from prominent lawmakers across ideological lines.
Military Focus: Its focus on active-duty service members and veterans resonates strongly with policymakers due to the urgent need to address suicide and mental health crises in these populations.
Likelihood: With parts of the legislation already integrated into law and strong bipartisan support, this bill is likely to continue gaining traction for broader implementation by 2026.
Overall Outlook
Both bills are positioned favorably due to bipartisan backing and increasing recognition of the therapeutic potential of psychedelics. The Breakthrough Therapies Act may face more hurdles due to its broader implications for drug policy, while Crenshaw's bill benefits from its targeted focus on military mental health care. Passage by 2026 is plausible for both, especially with continued advocacy and public support.
Positive Impacts:
Expansion of R&D Opportunities: By reducing regulatory barriers, the Act could encourage pharmaceutical companies to invest in psychedelic drug development, potentially creating a new market for mental health treatments.
Market Growth: The global psychedelic drugs market is projected to reach $7 billion by 2026, and this bill could accelerate growth by enabling more clinical trials and eventual commercialization.
Cost Savings in Healthcare: Psychedelic therapies have shown promise in treating conditions like PTSD and depression, which are costly to manage with traditional methods. This could reduce long-term healthcare expenditures.
Increased Government Funding: Federal grants for psychedelic research would provide financial support to pharmaceutical companies and academic institutions, fostering innovation.
Military Market Expansion: The Department of Defense's involvement could create a niche market for psychedelic therapies tailored to veterans and active-duty service members.
Increased R&D Spending: Psychedelic drug development would likely see a surge in investment, contributing to the industry's overall economic output (which was $2.3 trillion globally in 2022).
Shift in Innovation Priorities: Companies may prioritize mental health solutions over other therapeutic areas due to the growing demand for effective treatments.
Pricing Pressures: As these therapies become mainstream, pricing models will be scrutinized, especially if government programs like Medicare cover them.
Conclusion
If passed, these bills could significantly boost innovation and market growth in the pharmaceutical sector by legitimizing psychedelics as therapeutic tools. However, challenges such as regulatory hurdles, competition from smaller players, and ethical concerns will shape how quickly and effectively the industry capitalizes on these opportunities. By 2026, the combined impact of these legislative efforts could position psychedelics as a transformative segment within the broader pharmaceutical landscape.
I only know of two Companies in the world that are accredited with both GMP and MDMA and Psoliscobin.
My rationale of many on why BXN is an outright buy. For what it's worth and this view is subjective at the moment. This may be like a Bank.
My thoughts, if I was on the BoD, I would be entertain futuristic discussion on a USA based LLC, not a NASDAQ listing though. The ATO taxation implications for OS Companies change around June 2025 and may not be amiable.
Kpax
(20min delay)